Huang, Zuie Chin 黃瑞瑨
Main board
Organisation | Position | From | Until | Total Return |
CAGR total return |
CAGR relative return |
||
---|---|---|---|---|---|---|---|---|
1 | Alaunos Therapeutics, Inc. | ChChairman | 2021-01-01 | 2023 | ||||
2 | * | AUTO ITALIA HOLDINGS LIMITED | EDExecutive Director | 2020-07-27 | 2023-07-27 | -18.60% | -6.64% | -2.47% |
3 | CASI Pharmaceuticals, Inc. | DirDirector | 2013-04 | 2023 | ||||
4 | Connect Biopharma Holdings Limited | DirDirector | 2024 | |||||
5 | * | Genscript Biotech Corporation | NEDNon-Executive Director | 2015-08-24 | 2018-01-05 | 1,876.61% | 338.78% | 259.62% |
6 | * | Kindstar Globalgene Technology, Inc. | NEDNon-Executive Director | 2012-01-30 | -88.40% | -49.64% | -43.64% | |
7 | Kleiner Perkins Caufield & Byers China | Mng PartnerManaging Partner | 2011 | |||||
8 | * | LEE'S PHARMACEUTICAL HOLDINGS LIMITED | NEDNon-Executive Director | 2024-07-02 | 3.42% | |||
9 | MAAVRX LTD | DirDirector | 2021-01-08 | |||||
10 | Windtree Therapeutics, Inc. | ChChairman | 2019 | 2023 | ||||
11 | Ziopharm Oncology, Inc. | DirDirector | ||||||
Average | 94.17% | 71.17% |
Some data are hidden to fit your display. Rotate?
Total returns are measured from the latest of the start date, the appointment date and 3-Jan-1994 until the earliest of the end date, the resignation/removal date and the last trading date. CAGR is the annualised return and is not shown for periods under 180 days. Relative returns are to the Tracker Fund of HK (2800), starting from the latest of 12-Nov-1999, the appointment date and the chosen start date.
* = is or was HK primary-listed
Sign up for our free newsletter
Recommend Webb-site to a friend
Copyright & disclaimer, Privacy policy